Search
Magnesium citrate
go.drugbank.com/drugs/DB11110ApprovedInvestigational[T215] Magnesium citrate is considered by the FDA as an approved inactive ingredient for approved drug products under the specifications of oral administration of a maximum concentration of 237 mg. … [L2831] It is also considered as an active ingredient in over-the-counter products.[L1113]
Mixtures: Calcium Magnesium Plus Vitamin D Liquid, Calcium and Magnesium Citrate With Vitamin DCaplacizumab
go.drugbank.com/drugs/DB06081ApprovedInvestigationalCaplacizumab was developed by Ablynx, a Sanofi company and FDA approved on February 6, 2019,[L5302] and approved previously by the EU in October 2018 as a combination therapy with plasma exchange and immunosuppression … [A174634]In December 2025, the FDA expanded this indication to include pediatric patients aged 12 years and older with aTTP, in the same combination regimen.[L54958,L54963]
Vedolizumab
go.drugbank.com/drugs/DB09033ApprovedInvestigational[L48216] Vedolizumab was developed by Takeda and approved by the FDA under the brand name ENTYVIO for the maintenance therapy of moderately to severely active Ulcerative Colitis and Crohn’s Disease … of vedolizumab against α4β7 integrin has been thought to contribute to its more favorable safety profile compared to its predecessor natalizumab, the first integrin receptor antagonist approved by the FDA
Erdosteine
go.drugbank.com/drugs/DB05057ApprovedInvestigationalErdosteine is a drug that causes a breakdown of mucus, also known as a mucolytic agent. It is a thiol derivative produced for the clinical management of chronic obstructive bronchitis, in addition to infective exacerbations of chronic br...
Iobenguane
go.drugbank.com/drugs/DB06704ApprovedInvestigationalFDA approved on September 19, 2008. … The radioisotope used can either be iodine-123 for imaging or iodine-131 for destruction of tissues that metabolize noradrenaline.
Products: IOBENGUANO [131 I] GE HEALTHCARE DLunsotogene parvec
go.drugbank.com/drugs/DB18278ApprovedInvestigational[L56136] On April 23, 2026, the FDA granted accelerated approval for the treatment of pediatric and adult patients with severe-to-profound hearing loss associated with molecularly confirmed biallelic … Lunsotogene parvec is a first-in-class dual adeno-associated virus serotype 1 vector-based gene therapy developed to address an unmet medical need for OTOF-related sensorineural hearing loss.
Synonyms: DB-OTODecitabine
go.drugbank.com/drugs/DB01262ApprovedInvestigational[A2263, A2264, A2265, A215317, L14962] Decitabine was developed by MGI Pharma/SuperGen Inc. and was approved by the FDA for the treatment of MDS on February 5, 2006. … [L14962] It is also available as an oral combination product together with the cytidine deaminase inhibitor [cedazuridine].
Synonyms: 4-amino-1-(2-deoxy-β-D-erythro-pentofuranosyl)-s-triazin-2(1H)-onePotassium hydroxide
go.drugbank.com/drugs/DB11153ApprovedPotassium hydroxide, also known as _lye_ is an inorganic compound with the chemical formula _KOH_. … [L1946,L1951] This ingredient has been considered as generally safe as a direct human food ingredient by the FDA, based upon the observance of several good manufacturing practice conditions of use.
Synonyms: hydroxyde de potassiumSotagliflozin
go.drugbank.com/drugs/DB12713ApprovedInvestigational[A244470,A244499] Sotagliflozin was approved by the EMA under the brand name "Zynquista" on April 26, 2019, for the treatment of type 1 diabetes. … [L39739] On March 22, 2022, the marketing authorization of sotagliflozin for the treatment of type 1 diabetes mellitus was withdrawn by the EMA due to commercial reasons.
Ipecac
go.drugbank.com/drugs/DB13293ApprovedWithdrawn[L1113] The FDA does not have currently any approved product containing ipecac, however, ipecac as an ingredient is accepted to be sold over the counter in packages of 1 fluid ounce (30 ml) for the emergency … [L2753] Ipecac was approved by Health Canada as an OTC but all those products are now discontinued.